Pharmacogenetic influences on mycophenolate therapy

Pharmacogenomics

Volumn 11, Issue 3, 2010, Pages 369-390

  Barraclough, Katherine A ^a   Lee, Katie J ^b   Staatz, Christine E ^b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Mycophenolate; Mycophenolic acid; Pharmacodynamics; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics; Polymorphism

Indexed keywords

ABACAVIR; CORTICOSTEROID; CYCLOSPORIN A; DIDANOSINE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B7; INOSINATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; ORGANIC ANION TRANSPORTER; RAPAMYCIN; STAVUDINE; TACROLIMUS; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BILIARY EXCRETION; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSPORT; GENE ACTIVITY; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOW DRUG DOSE; PHARMACOGENOMICS; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG MONITORING; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSPLANTS;

EID: 77949585081     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.9     Document Type: Review

References (108)

1. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345(8961), 1321-1325 (1995).
2. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 61(7), 1029-1037 (1996).
3. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study group. Transplantation 60(3), 225-232 (1995).
4. Meier-Kriesche HU, Li S, Gruessner RW et al.: Immunosuppression: evolution in practice and trends, 1994-2004. Am. J. Transplant. 6(5 Pt 2), 1111-1131 (2006).
5. Shaw LM, Kaplan B, Denofrio D, Korecka M, Brayman Kl: Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther. Drug Monit. 22(1), 14-19 (2000).
6. van Gelder T, Silva H, De Fijter H et al.: Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fxed-dose concentration-controlled trial. Transplantation 86, 1043-1051 (2008).
7. Le Meur Y, Buchler M, Thierry A et al.: Individualized mycophenolate mofetil dosing based on drug exposure signifcantly improves patient outcomes after renal transplantation. Am. J. Transplant. 7(11), 2496-2503 (2007).
8. van Gelder T, Hilbrands LB, Vanrenterghem Y et al.: A randomized double-blind, multicenter plasma concentration controlled study of the safety and effcacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68(2), 261-266 (1999).
9. Weber LT, Shipkova M, Armstrong VW et al.: The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J. Am. Soc. Nephrol. 13(3), 759-768 (2002).
10. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P: Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am. J. Transplant. 4(7), 1079-1083 (2004).
11. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y: Clinical effcacy and toxicity profle of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin. Pharmacol. Ther. 75(5), 434-447 (2004).
12. Atcheson BA, Taylor PJ, Mudge DW et al.: Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br. J. Clin. Pharmacol. 59(3), 271-280 (2005).
13. Gaston RS, Kaplan B, Shah T et al.: Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the opticept trial. Am. J. Transplant. 9(7), 1607-1619 (2009).
14. Weimert NA, Derotte M, Alloway RR, Woodle ES, Vinks AA: Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther. Drug Monit. 29(2), 141-149 (2007).
15. Glander P, Hambach P, Braun KP et al.: Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. 4(12), 2045-2051 (2004).
16. De Winter BC, Mathot RA, van Hest RM, van Gelder T: Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? Expert Opin. Drug Metab. Toxicol. 3(2), 251-261 (2007).
17. Knight SR, Morris PJ: Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 85(12), 1675-1685 (2008).
18. Barraclough KA, Staatz CE, Isbel NM, Johnson DW: Therapeutic monitoring of mycophenolate in transplantation: is it justifed? Curr. Drug Metab. 10(2), 179-187 (2009).
19. Evans WE, Mcleod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
20. Staatz CE, Goodman LK, Tett SE: Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors: part 1. Clin. Pharmacokinet. (In press
21. Kiang TK, Ensom MH, Chang TK: UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106(1), 97-132 (2005).
22. Girard H, Court MH, Bernard O et al.: Identifcation of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14(8), 501-515 (2004).
23. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identifcation of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos. 33(1), 139-146 (2005).
24. Bernard O, Guillemette C: The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. 32(8), 775-778 (2004).
25. Schutz E, Shipkova M, Armstrong V W, Wieland E, Oellerich M: Identifcation of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin. Chem. 45(3), 419-422 (1999).
26. Shipkova M, Armstrong V W, Wieland E et al.: Identifcation of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br. J. Pharmacol. 126(5), 1075-1082 (1999).
27. Shipkova M, Armstrong V W, Kuypers D et al.: Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther. Drug Monit. 23(6), 717-721 (2001).
28. Shipkova M, Armstrong V W, Oellerich M, Wieland E: Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 25(1), 1-16 (2003).
29. Kuypers DR, Claes K, Evenepoel P et al.: Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not refected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J. Clin. Pharmacol. 43(8), 866-880 (2003).
30. van Gelder T, Gafner N; on Behalf of All FDCC Investigators: Mycophenolic acid plasma concentrations and acute rejection rate in high risk versus low risk renal transplant patients receiving mycophenolate mofetil. Transplantation 86(2S), 39 (2008) (Abstract 109).
31. Djebli N, Picard N, Rerolle Jp, Le Meur Y, Marquet P: Infuence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet. Genomics 17(5), 321-330 (2007).
32. Guillemette C: Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3(3), 136-158 (2003).
33. Rosso Felipe C, de Sandes T V, Sampaio EL, Park SI, Silva HT Jr, Medina Pestana JO: Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant. Proc. 41(5), 1441-1455 (2009).
34. Li YQ, Prentice DA, Howard ML, Mashford ML, Desmond PV: The effect of hormones on the expression of fve isoforms of UDP-glucuronosyltransferase in primary cultures of rat hepatocytes. Pharm. Res. 16(2), 191-197 (1999).
35. Courtois A, Payen L, Guillouzo A, Fardel O: Up-regulation of multidrug resistance-associated protein 2 (MRP2) expression in rat hepatocytes by dexamethasone. FEBS Lett. 459(3), 381-385 (1999).
36. Turncliff RZ, Meier PJ, Brouwer KL: Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 32(8), 834-839 (2004
37. Pulaski L, Kania K, Ratajewski M, Uchiumi T, Kuwano M, Bartosz G: Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J. Steroid Biochem. Mol. Biol. 96(3-4), 229-234 (2005).
38. Gregoor PJ, De Sevaux RG, Hene RJ et al.: Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 68(10), 1603-1606 (1999).
39. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 62(3), 1060-1067 (2002).
40. van Hest RM, Mathot RA, Pescovitz MD Gordon R, Mamelok RD, van Gelder T: Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-ana lysis of mycophenolic acid in renal transplant recipients. J. Am. Soc. Nephrol. 17(3), 871-880 (2006).
41. Kuypers DRJ, Verleden G, Naesens M, Vanrenterghem Y: Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diposphate-glucuronosyltransferase. Clin. Pharmacol. Ther. 78(1), 81-88 (2005).
42. Naesens M, Kuypers DR, Streit F et al.: Rifampicin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin. Pharmacol. Ther. 80(5), 509-521 (2006).
43. Cattaneo D, Bitto A, Baldelli S, Cortinovis M: Pharmacokinetic/ pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report. Transplantation 85(6) 921-922 (2008).
44. Konig J, Seithel A, Gradhand U, Fromm MF: Pharmacogenomics of human OATP transporters. Naunyn. Schmiedebergs Arch. Pharmacol. 372(6), 432-443 (2006).
45. Miura M, Satoh S, Inoue K et al.: Infuence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(12), 1161-1169 (2007).
46. Miura M, Kagaya H, Satoh S et al.: Infuence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther. Drug Monit. 30(5), 559-564 (2008).
47. Picard N, Yee SW, Woillard JB et al.: The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther. 87(1), 100-108 (2009).
48. Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn. Schmiedebergs Arch. Pharmacol. 368(5), 415-420 (2003).
49. Yu XQ, Xue CC, Wang G, Zhou SF: Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr. Drug Metab. 8(8), 787-802 (2007).
50. Mottino AD, Hoffman T, Jennes L, Vore M: Expression and localization of multidrug resistant protein MRP2 in rat small intestine. J. Pharmacol. Exp. Ther. 293(3), 717-723 (2000).
51. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y: Multidrug resistance protein 2 genetic polymorphisms infuence mycophenolic acid exposure in renal allograft recipients. Transplantation 82(8), 1074-1084 (2006).
52. Bullingham RE, Nicholls A, Hale M: Pharmacokinetics of mycophenolate mofetil (rs61443): a short review. Transplant. Proc. 28(2), 925-929 (1996).
53. Bullingham RE, Nicholls AJ, Kamm BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34(6), 429-455 (1998).
54. Uwai Y, Motohashi H, Tsuji Y, Ueo H, Katsura T, Inui K: Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem. Pharmacol. 74(1), 161-168 (2007).
55. Hesselink DA, van Hest RM, Mathot RA et al.: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. 5(5), 987-994 (2005).
56. Paulusma CC, Bosma PJ, Zaman GJ et al.: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271(5252), 1126-1128 (1996).
57. Smak Gregoor PJ, van Gelder T, Hesse CJ, van Der Mast BJ, van Besouw NM, Weimar W: Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol. Dial. Transplant. 14(3), 706-708 (1999).
58. Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet. 46(1), 13-58 (2007).
59. Wolff NA, Burckhardt BC, Burckhardt G, Oellerich M, Armstrong VW: Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. Nephrol. Dial. Transplant. 22(9), 2497-2503 (2007).
60. Allison AC: Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl. 1), S2-S8 (2005).
61. Jain J, Almquist SJ, Ford PJ et al.: Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem. Pharmacol. 67(4), 767-776 (2004).
62. Sombogaard F, Peeters AM, Baan CC et al.: Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther. Drug Monit. 31(5), 549-556 (2009).
63. Senda M, Natsumeda Y: Tissue-differential expression of two distinct genes for human IMP dehydrogenase (e.C.1.1.1.205). Life Sci. 54(24), 1917-1926 (1994).
64. Carr SF, Papp E, Wu JC, Natsumeda Y: Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 268(36), 27286-27290 (1993).
65. Langman LJ, Legatt DF, Halloran PF, Yatscoff RW: Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 62(5), 666-672 (1996).
66. Glander P, Hambach P, Braun KP et al.: Effect of mycophenolate mofetil on IMP dehydrogenase after the frst dose and after long-term treatment in renal transplant recipients. Int. J. Clin. Pharmacol. Ther. 41(10), 470-476 (2003).
67. Marfo K, Greenstein S: Antiretroviral and immunosuppressive drug-drug interactions in human immunodefciency virus-infected liver and kidney transplant recipients. Transplant. Proc. 41, 3796-3799 (2009).
68. Girard H, Villeneuve L, Court MH et al.: The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos. 34(7), 1220-1228 (2006).
69. Cheng Z, Radominska-Pandya A, Tephly TR: Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch. Biochem. Biophys. 356(2), 301-305 (1998).
70. Mojarrabi B, Mackenzie PI: Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. Biochem. Biophys. Res. Commun. 247(3), 704-709 (1998).
71. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C: Infuence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab. Dispos. 34(9), 1539-1545 (2006).
72. Huang YH, Galijatovic A, Nguyen N et al.: Identifcation and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 12(4), 287-297 (2002).
73. Bhasker CR, Mckinnon W, Stone A et al.: Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical signifcance. Pharmacogenetics 10(8), 679-685 (2000).
74. Sawyer MB, Innocenti F, Das S et al.: A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73(6), 566-574 (2003).
75. Thibaudeau J, Lepine J, Tojcic J et al.: Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 66(1), 125-133 (2006).
76. Holthe M, Klepstad P, Zahlsen K et al.: Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. 58(5), 353-356 (2002).
77. Coffman BL, King CD, Rios GR, Tephly TR: The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 26(1), 73-77 (1998).
78. Court MH, Krishnaswamy S, Hao Q et al.: Evaluation of 3́-azido-3́-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specifcity and infuence of the UGT2B7*2 polymorphism. Drug Metab. Dispos. 31(9), 1125-1133 (2003).
79. Duguay Y, Baar C, Skorpen F, Guillemette C: A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with signifcant impact on promoter activity. Clin. Pharmacol. Ther. 75(3), 223-233 (2004).
80. Seithel A, Glaeser H, Fromm MF, Konig J: The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin. Drug Metab. Toxicol. 4(1), 51-64 (2008).
81. Moriya Y, Nakamura T, Horinouchi M et al.: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 25(10), 1356-1359 (2002).
82. Meyer Zu Schwabedissen HE, Jedlitschky G, Gratz M et al.: Variable expression of MRP2 (ABCC2) in human placenta: infuence of gestational age and cellular differentiation. Drug Metab. Dispos. 33(7), 896-904 (2005).
83. Zhou Q, Sparreboom A, Tan Eh et al.: Pharmacogenetic profling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol. 59(4), 415-424 (2005).
84. Itoda M, Saito Y, Soyama A et al.: Polymorphisms in the ABCC2 (CMOAT/ MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5́-untranslated region and exon 28. Drug Metab. Dispos. 30(4), 363-364 (2002).
85. Innocenti F, Undevia S, Chen PEA: Pharmacogenetic ana lysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: evidence for a functional variant of ABCC2. J. Clin. Oncol. 22, S2010 (2004) (Abstract
86. Hirouchi M, Suzuki H, Itoda M et al.: Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. 21(5), 742-748 (2004).
87. Wang J, Yang JW, Zeevi A et al.: IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin. Pharmacol. Ther. 83(5), 711-717 (2008).
88. Winnicki W, Weigel G, Sunder-Plassmann G, Bajari T, Winter B, Herkner H, Sengoelge G. An inosine 5-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. Pharmacogenomics J. 10(1), 70-76 (2009).
89. Wang J, Zeevi A, Webber S et al.: A novel variant l263F in human inosine 5́-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet. Genomics 17(4), 283-290 (2007).
90. Garat A, Cauffez C, Hamdan-Khalil R et al.: IMPDH2 genetic polymorphism: a promoter single-nucleotide polymorphism disrupts a cyclic adenosine monophosphate response element. Genet. Test Mol. Biomarkers 13(6), 841-1784 (2009).
91. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y: The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 78(4), 351-361 (2005).
92. Kuypers DR, De Jonge H, Naesens M et al.: Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin. Ther. 30(4), 673-683 (2008).
93. Sanchez-Fructuoso AI, Maestro ML, Calvo N et al.: The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its infuence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant. Proc. 41(6), 2313-2316 (2009).
94. Levesque E, Delage R, Benoit-Biancamano MO et al.: The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profle of mycophenolic acid after a single oral dose in healthy volunteers. Clin. Pharmacol. Ther. 81(3), 392-400 (2007).
95. van Schaik RH, van Agteren M, De Fijter JW et al.: UGT1A9-275T>A/- 2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86(3), 319-327 (2009).
96. Johnson LA, Oetting WS, Basu S, Prausa S, Matas A, Jacobson PA: Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modifed by calcineurin inhibitors. Eur. J. Clin. Pharmacol. 64(11), 1047-1056 (2008).
97. van Gelder T, Le Meur Y, Shaw LM et al.: Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug Monit. 28(2), 145-154 (2006).
98. Baldelli S, Merlini S, Perico N et al.: C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8(9), 1127-1141 (2007).
99. Jiao Z, Ding JJ, Shen J et al.: Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the infuence of polymorphisms in UGT1A9. Br. J. Clin. Pharmacol. 65(6), 893-907 (2008).
100. Inoue K, Miura M, Satoh S et al.: Infuence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther. Drug Monit. 29(3), 299-304 (2007).
101. Kagaya H, Inoue K, Miura M et al.: Infuence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(3), 279-288 (2007).
102. Zhang WX, Chen B, Jin Z et al.: Infuence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 38(11), 1422-1436 (2008).
103. Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI: Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther. Drug. Monit. 31(5), 542-548 (2009).
104. van Agteren M, Armstrong V W, van Schaik RH et al.: AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther. Drug Monit. 30(4), 439-444 (2008).
105. Sombogaard F, van Schaik RH, Mathot RA et al.: Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. Pharmacogenet. Genomics 19(8), 626-634 (2009).
106. Grinyo J, Vanrenterghem Y, Nashan B et al.: Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl. Int. 21(9), 879-891 (2008).
107. Suzuki H, Sugiyama Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 54(10), 1311-1331 (2002).
108. Williams JA, Johnson K, Paulauskis J, Cook J: So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J. Clin. Pharmacol. 46(3), 258-264 (2006).